ACCENDRA HEALTH INC/VA/ Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | $697.3M | — | -$150.3M | — | $26.5M | -$1.94 |
| Q2 FY202510-Q · 2025-06-30 | $681.9M | — | -$869.1M | — | -$39.7M | -$11.30 |
| Q1 FY202510-Q · 2025-03-31 | $2.6B | — | -$25.0M | — | $60.1M | -$0.32 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $4.0B | $4.5B | $32.8M | -$429.5M |
| Q2 FY202510-Q | $4.2B | $4.4B | $38.3M | -$27.4M |
| Q1 FY202510-Q | $4.9B | $4.3B | $59.4M | $154.4M |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | $26.5M | -$150.3M | — | 77,299,000 |
| Q2 FY202510-Q | -$39.7M | -$869.1M | — | 77,197,000 |
| Q1 FY202510-Q | $60.1M | -$25.0M | $526.0M | 77,220,000 |
Filings
(4)Methodology
Every figure on this page is pulled directly from ACCENDRA HEALTH INC/VA/'s own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].